Literature DB >> 17365933

Culture-negative peritonitis: a fifteen-year review.

Kuan-Hsing Chen1, Chiz-Tzung Chang, Shun-Man Weng, Chun-Chen Yu, Ji-Tseng Fang, Jeng-Yi Huang, Chih-Wei Yang, Cheng-Chieh Hung.   

Abstract

Peritonitis is a serious complication in peritoneal dialysis (PD) patients; however, the clinical outcome of culture-negative peritonitis (CNP) is controversial. This retrospective study of CNP attempts to resolve this controversy. In 813 episodes of peritonitis, 202 episodes of CNP in 152 PD patients were reviewed. Two different methods of effluent culture were utilized during the study period. The incidence of CNP was lower with 50 ml centrifugation culture than 10 ml direct inoculation culture (20.7% vs. 35.7%; p < 0.05). The overall cure rate of CNP was greater than 80% of patients receiving cefamezine and gentamicin as initial therapy. Relapse within 30 days after completion of treatment happened in 9.6% of cases, and antibiotic therapy failed in 8.1% of CNP cases. In comparison with cured patients, patients with relapse or treatment failure are older (62.0 +/- 15.0 years vs. 54.3 +/- 15.3 years; p = 0.007) and have a higher rate of abdominal pain (91.4% vs. 69.3%; p = 0.007) and greater need for salvage therapy (54.3 % vs. 11.0%; p < 0.001). A history of antibiotic use or peritonitis within 30 days before onset of CNP was noted in 23.3% and 12.5% of cases, respectively, but was not associated with clinical outcome. The clinical outcome of CNP was benign in this study. Older age, abdominal pain, and need for salvage therapy were associated with an increased risk for relapse and treatment failure in CNP cases. Moreover, 50 ml centrifugation culture method was better than 10 ml direct inoculation culture in reducing the incidence of CNP.

Entities:  

Mesh:

Year:  2007        PMID: 17365933     DOI: 10.1080/08860220601098847

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  7 in total

1.  Peritonitis and exit site infections in First Nations patients on peritoneal dialysis.

Authors:  Ainslie Hildebrand; Paul Komenda; Lisa Miller; Claudio Rigatto; Mauro Verrelli; Amy R Sood; Chris Sathianathan; Martina Reslerova; Loretta Eng; Amanda Eng; Manish M Sood
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-19       Impact factor: 8.237

Review 2.  Evidence-based medicine: An update on treatments for peritoneal dialysis-related peritonitis.

Authors:  Pasqual Barretti; João Vitor Pereira Doles; Douglas Gonçalves Pinotti; Regina Paolucci El Dib
Journal:  World J Nephrol       Date:  2015-05-06

3.  Novel predictors of peritonitis-related outcomes in the BRAZPD cohort.

Authors:  Thyago Proença de Moraes; Marcia Olandoski; Jaqueline C T Caramori; Luis C Martin; Natália Fernandes; José Carolino Divino-Filho; Roberto Pecoits-Filho; Pasqual Barretti
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

4.  Clinical characteristics and outcomes of "silent" and "non-silent" peritonitis in patients on peritoneal dialysis.

Authors:  Jie Dong; Suping Luo; Rong Xu; Yuan Chen; Ying Xu
Journal:  Perit Dial Int       Date:  2012-08-01       Impact factor: 1.756

5.  Pathogen-specific local immune fingerprints diagnose bacterial infection in peritoneal dialysis patients.

Authors:  Chan-Yu Lin; Gareth W Roberts; Ann Kift-Morgan; Kieron L Donovan; Nicholas Topley; Matthias Eberl
Journal:  J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 10.121

Review 6.  Efficacy of antibiotic therapy for peritoneal dialysis-associated peritonitis: a proportional meta-analysis.

Authors:  Pasqual Barretti; João Vitor Pereira Doles; Douglas Gonçalves Pinotti; Regina El Dib
Journal:  BMC Infect Dis       Date:  2014-08-18       Impact factor: 3.090

7.  Cefazolin Plus Ceftazidime versus Cefazolin Monotherapy in the Treatment of Culture-Negative Peritonitis: A Retrospective Cohort Study.

Authors:  Krit Kovitangkoon; Eakalak Lukkanalikitkul; Pongsai Wiangnon; Theenatchar Chunghom; Sirirat Anutrakulchai; Judith Blaine; Pantipa Tonsawan
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-02-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.